905710-67-0

Upstream product

• 906673-56-1 1-(2′-bromo-5′-fluorophenyl)ethan-1-ol 
• 107-30-2 chloromethyl methyl ether 
• 94569-84-3 2-bromo-5-fluorobenzaldehyde 

Relevant academic research and scientific papers

Hydrolytically-Resistant Boron-Containing Therapeutics And Methods Of Use

Compositions and methods of use of boron derivatives, including benzoxaboroles, benzazaboroles and benzthiaboroles, as therapeutic agents for treatment of diseases caused by fungi, yeast, bacteria or viruses are disclosed, as well as methods for synthesis of said agents and compositions thereof.

Compounds for the Treatment of Periodontal Disease

Compounds, compositions and methods are provided which are useful in the treatment of periodontal disease.

Boron-containing small molecules

This invention relates to compounds useful for treating fungal infections, more specifically topical treatment of onychomycosis and/or cutaneous fungal infections. This invention is directed to compounds that are active against fungi and have properties that allow the compound, when placed in contact with a patient, to reach the particular part of the skin, nail, hair, claw or hoof infected by the fungus. In particular the present compounds have physiochemical properties that facilitate penetration of the nail plate.

Discovery of a new boron-containing antifungal agent, 5-fluoro-1,3-dihydro- 1-hydroxy-2,1-benzoxaborole (AN2690), for the potential treatment of onychomycosis

A structure-activity relationship investigation for a more efficacious therapy to treat onychomycosis, a fungal infection of the toe and fingernails, led to the discovery of a boron-containing small molecule, 5-fluoro-1,3-dihydro- 1-hydroxy-2,1-benzoxaborole (AN2690), which is currently in clinical trials for onychomycosis topical treatment.